The New World of Medicine: Stem Cell Therapy
By NEVAGiles23
In this video I will lay out my thinking as to why stem cell therapy is the next boom; it will in fact, change the world. What do you think?
More here:
Uncategorized
Comments Off on The New World of Medicine: Stem Cell Therapy |
July 27th, 2011
Lou Gehrig’s Disease (ALS): Stem Cell Therapy – A Patient’s Perspective
By Dr. Matthew Watson
(Part 7 of 8) Dan Desmond, spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010. Desmond has a Master of Arts in counseling psychology and is founding director of Family Focus Christian Counseling, Inc
Go here to read the rest:
Lou Gehrig's Disease (ALS): Stem Cell Therapy - A Patient's Perspective
Uncategorized
Comments Off on Lou Gehrig’s Disease (ALS): Stem Cell Therapy – A Patient’s Perspective |
July 26th, 2011
Clinical Advances in Adult Stem Cell Therapy – Dr. Jorge Paz Rodriguez (Miami)
By raymumme
Current treatments with Adipose-, Bone Marrow- and Cord Blood-derived stem cells. Autism, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis and Osteoarthritis treatments are outlined
See more here:
Clinical Advances in Adult Stem Cell Therapy - Dr. Jorge Paz Rodriguez (Miami)
Uncategorized
Comments Off on Clinical Advances in Adult Stem Cell Therapy – Dr. Jorge Paz Rodriguez (Miami) |
July 26th, 2011
Meditation May Help Women Cope With Hot Flashes
By Dr. Matthew Watson
(HealthDay News) -- An easy-to-learn meditation technique can help ease the hot flashes, night sweats and insomnia of menopause, a new study says.
The University of Massachusetts research showed that mindfulness training, based on a Buddhist meditation concept, reduced the distress associated with hot flashes and improved physical, psychosocial and sexual functioning.
"The findings are important because hormone replacement therapy, used to treat menopause symptoms in the past, has been associated with health risks," said study author James Carmody, an associate professor of medicine in the division of preventive and behavioral medicine.
About 40 percent of menopausal women suffer from hot flashes and night sweats, which undermine their quality of life, the researchers noted. But since hormone replacement therapy has been linked with an increased risk of heart disease, breast cancer and stroke, Carmody observed that "not only are women looking for alternative treatments, it is an NIH (National Institutes of Health) priority to find behavioral treatments Read more...
Cardiofy Heart Care Supplement
Integrative Medicine
Comments Off on Meditation May Help Women Cope With Hot Flashes |
July 24th, 2011
Comic-Con 2011: IN TIME shows promise with new trailer – Gordon and the Whale
By Dr. Matthew Watson
 USA Today | Comic-Con 2011: IN TIME shows promise with new trailer Gordon and the Whale IN TIME is an action/thriller and the child of GATTACA, the genetic engineering has just gotten better. In this world, you stop aging at 25 and then only have 1 year left unless you can buy, trade, or steal more. The rich can live forever, ... Comic-Con Interview: Andrew Niccol on Social Commentary, Ruining Film for ...Film School Rejects Comic-Con 2011: In Time Coverage and PanelUGO |
Uncategorized
Comments Off on Comic-Con 2011: IN TIME shows promise with new trailer – Gordon and the Whale |
July 24th, 2011
Biotechnology Bounces Back With 46% Rise in Venture Capital – San Francisco Chronicle
By Dr. Matthew Watson
 Citybizlist (press release) | Biotechnology Bounces Back With 46% Rise in Venture Capital San Francisco Chronicle July 20 (Bloomberg) -- Venture-capital funding in biotechnology companies jumped 46 percent in the second quarter, as investors looked to replenish their portfolios after an increase in acquisitions and initial public offerings. ... Biotech sees jump in VC fundingSan Francisco Business Times (blog) Venture Capital Investments Rise 19% In Q2 2011 To $7.5 Billion In 966 DealsPR Web (press release) Venture capitalists invest $13.75 million in South Carolina in second quarterCharleston Regional Business CNET all 145 news articles » |
Uncategorized
Comments Off on Biotechnology Bounces Back With 46% Rise in Venture Capital – San Francisco Chronicle |
July 24th, 2011
Pakistan can emerge as biotechnology leader – Pakistan Observer
By Dr. Matthew Watson
 The Express Tribune | Pakistan can emerge as biotechnology leader Pakistan Observer Lahore—Provincial Minister for Agriculture, Malik Ahmad Ali Aulakh has said that 21 century is the century of Biotechnology and Pakistan has tremendous potential to emerge as Biotechnology leader. Speaking at a seminar on Bio-technology at Lahore ... 21st century belongs to biotechnologyThe Nation, Pakistan Biotechnology: 'Pakistan has potential to be world leader'The Express Tribune |
Uncategorized
Comments Off on Pakistan can emerge as biotechnology leader – Pakistan Observer |
July 24th, 2011
New Report Details Uphill Battle to Solve the U.S.’s Pain Problem
By Dr. Matthew Watson
Chronic pain affects at least one in three adults in the U.S., which is more than the sum total of those with heart disease, cancer and diabetes combined. For many of these 116 million Americans, their pain is severe and eludes available treatments. In addition to the human suffering, the monetary cost of medical treatment and lost productivity has reached $635 billion a year. [More]
Uncategorized
Comments Off on New Report Details Uphill Battle to Solve the U.S.’s Pain Problem |
July 24th, 2011
The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper
By Dr. Matthew Watson
International Stem Cell Corp (OTCBB: ISCO), a biotechnology company focused on therapeutic biomedical research and cosmeceutical products, operating in the same industry as companies like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC), aims to become the premier supplier of human cells and cell based products to the rapidly growing regenerative medicine industry.
International Stem Cell Corp (OTCBB: ISCO) specializes in manufacturing pluripotent human “partheno-genetic” stem cells that can be converted into any of the many specific types of cells that will be needed as regenerative medicine moves from the laboratory to the hospital or physician’s office. ISCO’s cells have the same kind of ability to become any specific cell that might be needed for therapy as do the cells used by competitors like Geron Corporation (Nasdaq: GERN) and Advanced Cell Technology Inc. (OTCBB: ACTC). Unlike the cells used by these competitors, however, ISCO’s cells are not obtained from fertilized embryos that might otherwise mature into a human child. Instead, they are derived from un-fertilized human eggs that would otherwise be destroyed and have no capacity to become a human child. Thus, ISCO’s parthenogenetic stem cells have removed a major ethical barrier to the use of the most prolific class of stem cells available to science today. With its patent on using the parthenogenesis process to make the stem cells, the company plans to establish partnerships, collaborations and licensing agreements with larger pharmaceutical companies to eventually unlock significant shareholder value.
Please read the complete article at The OTC Investor here
Stem Cell Therapy
Comments Off on The OTC Investor Article – International Stem Cell (ISCO) Aims to Become the “Intel(tm) of the Stem Cell World” By Justin Kuepper |
July 24th, 2011
International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells
By Dr. Matthew Watson
CARLSBAD, Calif. (July 20, 2011) – International Stem Cell Corporation (OTCBB: ISCO) announced today the initiation of a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells.
The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO's proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson's Disease (PD).
ISCO uses unfertilized oocytes to create human parthenogenetic stem cells, an approach that offers a number of distinct advantages over other types of human stem cells. Like human embryonic stem cells (hESCs), hpSCs are pluripotent, and thus have the capacity to become almost any cell type in the body.
However, unlike hESCs, hpSCs can be created in a form such that cells from a single donor can be immunologically matched to millions of individuals.
Because no human embryos are ever damaged or destroyed in creating ISCO’s cells, they also avoid the ethical issues associated with embryonic hESC cells. ISCO maintains the world’s largest collection of research-grade hpSC lines.
Dr. Andrey Semechkin, the CEO of ISCO, comments: “The ability of neuronal cells to become a specific
type of neuron is one of the most important properties that these cells must have to be used in cell-based therapy of neurological disorders. These studies will bring us one step closer to our goal of being able to treat PD.”
Parkinson’s disease is a disease of the central nervous system that affects millions of people worldwide.
PD patients present a range of possible symptoms, some of which are known to be as a result of the loss of dopaminergic neurons in the mid brain. ISCO’s approach is first to derive neuronal cells successfully from hpSC and, second, to evaluate their safety, functionality and efficacy using a series of in-house in vitro and in vivo models.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com .
To subscribe to receive ongoing corporate communications, please click on the following link: http://
Forward-looking Statements
Statements pertaining to anticipated developments, the potential production and benefits of stem cell
lines, and other opportunities for the company and its subsidiaries, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
Contacts:
International Stem Cell Corporation
760-940-6383
Ruslan Semechkin, Ph.D.
Vice President
or:
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
# # #
Stem Cell Therapy
Comments Off on International Stem Cell Corporation Starts Series of Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells |
July 24th, 2011
Post Stem Cell Therapy Video for Cerebral Palsy
By JoanneRUSSELL25
Stem Cell Therapy for Cerebral Palsy done at Neurogen Brain and Spine Institute Pvt. Ltd.
The rest is here:
Post Stem Cell Therapy Video for Cerebral Palsy
Uncategorized
Comments Off on Post Stem Cell Therapy Video for Cerebral Palsy |
July 21st, 2011
Duffy Gets Stem Cell Therapy
By Dr. Matthew Watson
Kingsbury Animal Hospital in St. Louis performs it's first stem cell procedure on Duffy, a 10 year old Lab who suffers from arthritis.
Follow this link:
Duffy Gets Stem Cell Therapy
Uncategorized
Comments Off on Duffy Gets Stem Cell Therapy |
July 20th, 2011
Bone Marrow Stem Cell Donation
By Dr. Matthew Watson
In August 2009 I donated Bone Marrow Stem Cells via the apheresis procedure. I have been registered with the Australian Bone Marrow Donor Registry since 2001.
Follow this link:
Lou Gehrig’s Disease (ALS): UCSD Team’s Stem Cell Therapy Rationale
By raymumme
(Part 3 of 8) Don Cleveland, Ph.D. spoke at the "Spotlight on Disease Team Awards: ALS," an educational event presented at the CIRM Governing Board meeting on June 23, 2010
Read this article:
Lou Gehrig's Disease (ALS): UCSD Team's Stem Cell Therapy Rationale
Uncategorized
Comments Off on Lou Gehrig’s Disease (ALS): UCSD Team’s Stem Cell Therapy Rationale |
July 19th, 2011
From Surgical Repair to Stem Cell Repair: A Surgeon’s Journey by Leonard Smith MD, FACS
By daniellenierenberg
Dr. Smith focuses on understanding the natural process of how the body uses tissue stem cells and bone marrow stem cells, what people can do to facilitate or inhibit this natural process and how science can help us manage disease or aging with autologous or allogenic stem cell therapy.
View original post here:
From Surgical Repair to Stem Cell Repair: A Surgeon's Journey by Leonard Smith MD, FACS
Bone Marrow Stem Cells
Comments Off on From Surgical Repair to Stem Cell Repair: A Surgeon’s Journey by Leonard Smith MD, FACS |
July 19th, 2011
Bone Marrow Aspiration – Stem Cell Therapy
By NEVAGiles23
Stem Cell therapy is one form of Comprehensive Prolotherapy available for arthritis treatment, sports injury rehab, and chronic pain relief at Caring Medical and Rehabilitation Services. Our same-day procedure utilizes a person's own mesenchymal stem cells from bone marrow to treat joint degeneration
Go here to see the original:
Uncategorized
Comments Off on Bone Marrow Aspiration – Stem Cell Therapy |
July 18th, 2011
Book on Effectiveness of Heberprot-P Is Presented in Camagüey – Radio Cadena Agramonet
By Dr. Matthew Watson
 Radio Cadena Agramonet | Book on Effectiveness of Heberprot-P Is Presented in Camagüey Radio Cadena Agramonet Confidence of 25 Venezuelan patients in effectiveness of the Heberprot-P was exposed in the text “De nuevo al camino” by the camagueyan doctor Julio Baldomero Hernández, presented this Thursday in the Center for Genetic Engineering and Biotechnology of ... |
Uncategorized
Comments Off on Book on Effectiveness of Heberprot-P Is Presented in Camagüey – Radio Cadena Agramonet |
July 17th, 2011
Governors’ Biotechnology Scholarship Fund announces 2011 winners – Cecil Whig
By Dr. Matthew Watson
 SunHerald.com | Governors' Biotechnology Scholarship Fund announces 2011 winners Cecil Whig The Delaware Governors' Biotechnology Scholarship Fund Committee announced the recipients of this year's scholarship awards. Liudmila Mikhno, attending the University of Delaware and Liedeke Sweitzer, attending Delaware Technical and Community College ... Research and development partnership aims to benefit education, economyNewark Post |
Uncategorized
Comments Off on Governors’ Biotechnology Scholarship Fund announces 2011 winners – Cecil Whig |
July 17th, 2011
Anonymous targets biotechnology and oil giants – Inquirer
By Dr. Matthew Watson
Treehugger | Anonymous targets biotechnology and oil giants Inquirer By Inquirer Staff HACKTIVIST COLLECTIVE Anonymous has launched hacking campaigns against agricultural biotechnology giant Monsanto and energy companies with interests in the extraction of heavy crude oil from the Alberta tar sands. ... Monsanto biotechnology giant next target for AnonymousMyBroadband Monsanto Acknowledges Hack by Anonymous, Employee Details StolenITProPortal Hackers claim Monsanto strikeInformation Age |
Uncategorized
Comments Off on Anonymous targets biotechnology and oil giants – Inquirer |
July 17th, 2011
International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea
By Dr. Matthew Watson
International Stem Cell Corporation (ISCO) applauds the recent announcement by doctors at Sweden’s Karolinska University Hospital on the creation of the world’s first artificial trachea.
ISCO would like our followers to understand that the concept of growing cells on a scaffold to treat diseases is showing success in our own research as exemplified by the following:
1) Collaboration with Cytograft in growing artificial blood vessels for treatment of lower limb ischemia. We are extremely proud and gratified to see how our FibroLife media manufactured by ISCO’s subsidiary Lifeline Cell Technology is effective in growing cells on threads used to “weave” artificial blood by Cytograft (as announced in ISCO’s recent press releases).
2) The same technology is being used in ISCO’s work with Dr. Paul H. Chen wherein corneal epithelial cells are plated onto contact lenses (the “scaffold”) and used as a “living bandage” for laser eye surgery.
International Stem Cell Corporation will continue to pursue the use of its cells and cell culture products in the many developing fields of regenerative medicine.
Stem Cell Therapy
Comments Off on International Stem Cell Corporation Congratulates Sweden’s Karolinska University Hospital on the Creation of the World’s First Artificial Trachea |
July 17th, 2011